EW Edwards Lifesciences Stock Outlook 2026: TAVR Leadership, TMTT Expansion, and the Structural Heart Pure Play

Edwards Lifesciences (NYSE: EW) in 2026 is a company that has made an unusually clear strategic declaration: we do one thing, and we do it better than anyone else. Structural heart disease. That declaration became sharper with the $4.2 billion Critical Care divestiture to Becton Dickinson in 2024—a transaction that stripped away a stable but peripheral business to leave behind the pure structural heart narrative investors had long asked for.

The TAVR story is largely written. Edwards invented the commercial TAVR category, iterated faster than Medtronic through five device generations, accumulated the deepest clinical evidence base, and established the largest physician training infrastructure. That advantage doesn’t disappear overnight.

The TMTT story is still being written. Mitral and tricuspid valve diseases represent the remaining frontier of minimally invasive cardiac intervention—clinically relevant, technically demanding, and potentially as large as or larger than TAVR. Whether Edwards can replicate its TAVR dominance in TMTT defines the company’s next decade.

---

The Critical Care Divestiture: Why This Was the Right Decision

What Critical Care Was

Edwards’s Critical Care division manufactured the Swan-Ganz pulmonary artery catheter and related hemodynamic monitoring systems used in intensive care units globally. These are not glamorous products, but they are essential tools in the management of critically ill patients.

The business generated consistent revenue, had stable hospital relationships, and was profitable. It was not the problem.

Why It Had to Go

The divestiture logic reflects an opportunity cost argument. Edwards’s management had identified TMTT as a multi-billion dollar market opportunity requiring sustained R&D investment, multiple clinical trials, and a global commercial buildout over a decade. Carrying a separate Critical Care segment meant:

• Management time divided between structural heart innovation and ICU monitoring
• R&D capital shared between two unrelated disciplines
• Investor communications complicated by mixed growth profiles

At $4.2 billion, the transaction valued Critical Care at a reasonable earnings multiple. The proceeds funded a large share buyback, reduced the equity base, and signaled strategic discipline.

Post-Divestiture Business Profile

Segment	Revenue Character	Growth Rate
TAVR	Established, dominant	Mid-to-high single digit
TMTT	Emerging, high-investment	Pre-revenue to high growth
Surgical Structural Heart	Established, stable	Low-to-mid single digit

The three-segment picture is cleaner: two established franchises generating cash funding the TMTT investment phase.

---

TAVR Sapien: What Market Leadership Actually Means

The Five-Generation Advantage

Edwards received FDA approval for its first commercial TAVR system in 2011, roughly two years ahead of Medtronic’s initial US approval for CoreValve. That two-year head start translated into:

• Earlier physician training and fellowship programs
• First clinical trials establishing outcomes data in the highest-risk patients
• Initial hospital infrastructure investment favoring Edwards systems
• FDA approval in progressively lower-risk patients based on accumulated evidence

By the time competitive systems reached market, Edwards had established surgical volume, training relationships, and an implanting physician base that was already loyal.

The Low-Risk Trial Expansion

The pivotal moment in TAVR’s market development was the approval of TAVR in low-surgical-risk patients—previously only high-and-intermediate-risk patients were approved indications. The PARTNER 3 trial (Sapien 3) and the Evolut Low-Risk trial both established that TAVR outcomes were comparable to open surgery in younger, healthier patients.

This expanded the TAVR indication to a substantially larger population, and the evidence base was built around Sapien 3—helping sustain Edwards’s procedural volume advantage.

The Medtronic Evolut Competition

Medtronic’s Evolut system—currently the Evolut FX+—is the most credible TAVR competitor globally. The self-expanding design offers repositionability that some anatomies favor. Medtronic has been narrowing the gap in published clinical outcomes, and its global sales infrastructure is formidable.

The practical competitive dynamic: in hospitals where both systems are available, surgeon preference and past experience with each system is often decisive. Edwards’s strength in physician training programs—often run through university medical centers with high volume—reinforces its position.

Comparison Factor	Edwards Sapien 3 Ultra	Medtronic Evolut FX+
Deployment mechanism	Balloon-expandable	Self-expanding
Repositionability	No	Yes
Valve design	Bovine pericardium	Porcine pericardium
Anti-calcification	RESILIA technology	Varies by generation
Clinical trial volume	Largest globally	Second-largest

---

TMTT: Replicating the TAVR Playbook in Harder Territory

Why Mitral and Tricuspid Are More Complex

The aortic valve—TAVR’s target—sits in a relatively accessible anatomical position with circular geometry and manageable flow dynamics. The mitral and tricuspid valves present:

• Complex, non-circular annular geometry
• High pressure and flow environments (especially mitral)
• Proximity to other cardiac structures requiring precision navigation
• Diverse pathology types requiring different repair vs. replacement approaches

These factors explain why transcatheter mitral and tricuspid therapies have taken longer to develop than TAVR, and why clinical trial outcomes have been more variable across devices.

Edwards TMTT Pipeline in 2026

PASCAL Precision Transcatheter mitral and tricuspid valve repair device. Competes with Abbott’s MitraClip in mitral regurgitation, with design differences that may favor certain anatomies. The CLASP IID/IIF trial is the pivotal US data set for PASCAL—regulatory submission and approval timeline is the key catalyst.

EVOQUE Transcatheter tricuspid valve replacement. Tricuspid regurgitation has been the most undertreated valvular condition because surgery carries substantial risk in typically elderly, comorbid patients. EVOQUE offers a non-surgical option for a population without good alternatives. FDA approval timeline following trial data is the key milestone.

Tendyne Surgical mitral valve replacement system with CE Mark in Europe. Represents the surgical structural heart portfolio extension into the mitral space.

TMTT Revenue Ramp Timeline

The TMTT business is in early commercial stage—revenue is growing from a small base and contributing limited earnings while absorbing substantial R&D and market development costs. The commercial inflection likely requires broad US insurance coverage decisions and physician training at scale.

Analysts who model Edwards typically project TMTT becoming material to overall revenue in the 2027-2029 timeframe, contingent on trial results and FDA approvals. Delays in those approvals extend the investment period.

---

Japan and Asia: Reimbursement as the Market Unlock

Japan’s TAVR Opportunity

Japan’s healthcare system is characterized by universal coverage through National Health Insurance and significant government control over device pricing. When a new device category gains NHI reimbursement, adoption can accelerate quickly—providers can offer the procedure without exposing patients to unbounded out-of-pocket costs.

TAVR has been covered under Japan NHI, and Edwards has been building market presence there. As Japan’s population continues aging—the 75+ cohort is growing fastest—the procedural opportunity expands.

The specific reimbursement rate set by the Ministry of Health, Labour and Welfare (MHLW) for TAVR procedures influences hospital economics and adoption speed. Verification of current TAVR reimbursement levels in Japan requires checking MHLW fee schedule publications or Edwards investor relations materials.

South Korea and Greater Asia

South Korea’s health insurance system (NHIS) similarly covers TAVR, with adoption growing at major cardiac centers. The Korea national hospital network creates concentrated decision-making: approval at major academic centers (Seoul National University Hospital, Asan Medical Center, etc.) cascades to broader adoption.

---

The Medtronic Threat: Not Over Yet

Medtronic’s TAVR Persistence

Medtronic has invested consistently in TAVR iteration—Evolut FX+ is the latest generation, incorporating smaller delivery systems and refined deployment mechanics. Medtronic’s global commercial infrastructure is excellent, and its relationships with cardiac catheterization lab teams are extensive.

The bull case for Edwards assumes Medtronic’s market share gains plateau because Edwards’s data advantage and physician training infrastructure are durable. The bear case assumes Medtronic closes the clinical data gap and offers hospitals a credible alternative that gives procurement teams price leverage over Edwards.

Abbott and Boston Scientific as Secondary Competitors

Abbott’s Portico valve received FDA approval but has not achieved major US market share against Sapien 3. Boston Scientific’s ACURATE neo2 operates primarily in Europe with a CE Mark.

Neither represents the same competitive intensity as Medtronic. But a well-financed competitor improving its TAVR product over time is worth monitoring, particularly as TAVR indications potentially expand into even younger patients where long-term durability data becomes the differentiator.

---

Bull, Base, and Bear Scenarios

Bull Case

TAVR sustains high-single-digit growth driven by global procedure volume expansion and geographic growth in Asia. PASCAL CLASP trial data is favorable; FDA approval comes in 2026-2027, enabling commercial ramp. EVOQUE approval establishes Edwards in tricuspid replacement without a credible near-term competitor. Japan reimbursement proves accretive. Adjusted EPS grows 14-16% annually.

In this scenario, EW maintains or expands its premium valuation multiple, as the TMTT franchise justifies a longer runway than TAVR alone.

Base Case

TAVR grows in the 6-9% range. TMTT products gain regulatory approvals and begin commercial ramp, contributing modest but growing revenue by 2027. Medtronic maintains its current share level without material gains. Japan and Asia deliver mid-single-digit growth. Adjusted EPS grows 9-12% annually.

Bear Case

TAVR growth moderates below 5% as market penetration reaches saturation in high-income markets. TMTT trial results are mixed or approvals delayed, pushing commercial ramp to 2029+. Medtronic gains meaningful TAVR share through aggressive pricing or Evolut FX+ superiority data. Japan reimbursement disappoints. Edwards faces an earnings valley between slowing TAVR and late-arriving TMTT.

---

Comparing EW and SYK: Different Approaches to Medical Device Leadership

Both Edwards and Stryker (SYK) are elite medical device franchises with durable competitive moats. The structural differences:

Factor	EW	SYK
Technology focus	Catheter-based cardiac valves	Orthopedic robotics and implants
Installed base dynamics	Physician training and clinical data	Mako robot hardware with implant pull-through
Revenue diversity	Low (structural heart)	Moderate (ortho + MedSurg + neuro)
Growth driver	TAVR + TMTT market expansion	Mako ramp + aging demographics
Dividend	Minimal	Modest

EW is the more concentrated bet—higher potential upside from TMTT if it works, higher downside if TAVR growth disappoints simultaneously. SYK offers broader procedural volume diversification.

---

Related Posts

• JNJ Johnson & Johnson Stock Outlook 2026
• MRK Merck Stock Outlook 2026
• LLY Eli Lilly Stock Outlook 2026
• AAPL Apple Stock Outlook 2026
• SCHD Dividend ETF Guide 2026

---

Conclusion: A 10-Year Investment in the Next Frontier of Cardiac Medicine

Edwards Lifesciences has one of the clearest long-term investment narratives in medical devices: a company that invented a transformative cardiac therapy, dominated its early development, and is now attempting to replicate that process in the next anatomically adjacent valve territory.

The 2026 investment decision centers on willingness to fund that transition period. TAVR generates the cash. Critical Care proceeds funded the balance sheet reset. TMTT is the destination—but the trip requires patience through a capital-intensive R&D and commercial ramp.

Track PASCAL CLASP trial results, EVOQUE FDA submission timeline, Japan NHI adoption data, and Medtronic’s TAVR share evolution each quarter. These four variables will tell you whether Edwards’s TMTT transition is on plan or needs reassessment.

This article is for informational purposes only and does not constitute investment advice.